Trial record 3 of 4 for:    trevo

Trevo® Retriever Registry

This study is currently recruiting participants.
Verified January 2014 by Stryker Neurovascular
Information provided by (Responsible Party):
Stryker Neurovascular Identifier:
First received: January 15, 2014
Last updated: January 16, 2014
Last verified: January 2014

The purpose of the Trevo® Retriever Registry is to assess real world performance of the Trevo Retriever which is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke.

Ischemic Stroke

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 90 Days
Official Title: Stryker Neurovascular Trevo® Retriever Registry

Resource links provided by NLM:

Further study details as provided by Stryker Neurovascular:

Primary Outcome Measures:
  • Revascularization status assessment at the end of the Trevo Retriever procedure using the modified TICI score [ Time Frame: Modified TICI score assess at the end of the procedure ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • mRS assessment [ Time Frame: 90 days ] [ Designated as safety issue: Yes ]
    Assess the rate of participants with mRS </=2 to determine good clinial outcomes at 90 days.

Other Outcome Measures:
  • Assess the rates of device and procedure related serious adverse events (AEs) [ Time Frame: 90 days ] [ Designated as safety issue: Yes ]
  • Assess all cause mortality [ Time Frame: 90 days ] [ Designated as safety issue: Yes ]
    Report if cause of death is device or procedure related.

Estimated Enrollment: 300
Study Start Date: November 2013
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Mechanical thrombectomy, Trevo Retriever
Mechanical thrombectomy, Trevo Retriever

Detailed Description:

Trevo Retriever Registry is a prospective, open-label, consecutive enrollment, multi-center, international registry that may enroll a maximum of 300 patients at up to 40 sites worldwide. Revascularization status will be assessed at the end of the procedure using the modified TICI (Thrombolysis in Cerebral Infarction)score. Additional data collection will include:

  1. Day 90 mRS assessment
  2. Day 90 all cause mortality
  3. Neurological deterioration at 24 hours post procedure, defined as a four or more point increase in the NIHSS score from the baseline score
  4. Rates of device and procedure related serious adverse events (AEs)

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Acute ischemic stroke patients who may be referred for mechanical thrombectomy is used to removed thrombus in the neurovasculature


Inclusion Criteria:

  • Subjects experiencing acute ischemic stroke who are eligible for restoration of blood flow using any approved Trevo Retriever in the neurovasculature to remove thrombus
  • Trevo Retriever is the initial mechanical neuro-thrombectomy device used to remove the thrombus
  • Signed Informed Consent obtained
  • Subject willing to comply with the protocol follow-up requirements
  • Anticipated life expectancy of at least 3 months

Exclusion Criteria:

  • The subject is participating in another mechanical neuro-thrombectomy device trial or any other clinical trial where the study procedure or treatment might confound the study end point.
  Contacts and Locations
Please refer to this study by its identifier: NCT02040259

Contact: Paula P Schmidt, RN 510.413.2177

United States, Maryland
University of Maryland Medical Center Recruiting
Baltimore, Maryland, United States, 21201
Contact: Tim Miller, MD    410-328-5112   
Principal Investigator: Tim Miller, MD         
United States, New Jersey
Capital Health System Recruiting
Trenton, New Jersey, United States, 08638
Contact: Mandy J Binning, MD    609-394-6287   
Principal Investigator: Mandy J Binning, MD         
Sponsors and Collaborators
Stryker Neurovascular
Principal Investigator: Erol Veznedaroglu, MD Capital Health System, Trenton, NJ
Principal Investigator: Ronald Budzik, MD Riverside Methodist Hospital/ Ohio Health Research Institute, Columbus, OH
  More Information

No publications provided

Responsible Party: Stryker Neurovascular Identifier: NCT02040259     History of Changes
Other Study ID Numbers: T4025
Study First Received: January 15, 2014
Last Updated: January 16, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Stryker Neurovascular:
ischemic stroke
mechanical thrombectomy device

Additional relevant MeSH terms:
Pathologic Processes
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases processed this record on April 17, 2014